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AbstrACt
Objectives To evaluate the feasibility of a randomised 
trial of a modified, pre- existing, mindfulness meditation 
smartphone app for women with chronic pelvic pain.
Design Three arm randomised feasibility trial.
setting Women were recruited at two gynaecology clinics 
in the UK. Interventions were delivered via smartphone or 
computer at a location of participants choosing.
Participants Women were eligible for the study if they 
were over 18, had been experiencing organic or non- 
organic chronic pelvic pain for 6 months or more, and had 
access to a computer or smartphone. 90 women were 
randomised.
Interventions Daily mindfulness meditation delivered by 
smartphone app, an active control app which delivered 
muscle relaxation techniques, and usual care without app. 
Interventions were delivered over 60 days.
Primary and secondary outcome measures Outcomes 
included length of recruitment, follow- up rates, adherence 
to the app interventions, and clinical outcomes measured 
at baseline, two, three and 6 months.
results The target sample size was recruited in 145 days. 
Adherence to the app interventions was extremely low 
(mean app use 1.8 days mindfulness meditation group, 7.0 
days active control). Fifty- seven (63%) women completed 
6- month follow- up, and 75 (83%) women completed at 
least one postrandomisation follow- up. The 95% CIs for 
clinical outcomes were consistent with no benefit from 
the mindfulness meditation app; for example, mean 
differences in pain acceptance scores at 60 days (higher 
scores are better) were −2.3 (mindfulness meditation vs 
usual care, 95% CI: −6.6 to 2.0) and −4.0 (mindfulness 
meditation vs active control, 95% CI: −8.1 to 0.1).
Conclusions Despite high recruitment and adequate 
follow- up rates, demonstrating feasibility, the extremely 
low adherence suggests a definitive randomised trial of 
the mindfulness meditation app used in this study is not 
warranted. Future research should focus on improving 
patient engagement.
trial registration numbers NCT02721108; 
ISRCTN10925965; Results.
bACkgrOunD
Chronic pelvic pain in women is defined as 
intermittent or constant pain in the lower 
abdomen or pelvis for 6 or more months, 
and affects more than 24% of women world-
wide.1 It has considerable impact on patients’ 
quality of life, including their mental health 
and their income due to loss of working 
days and diminished work capacity.2 Chronic 
pelvic pain may or may not have an identi-
fiable pathology and has both physical and 
psychological contributors.3 Chronic pelvic 
pain is difficult to treat but health outcomes 
can be improved by psychological and life-
style interventions.4 5 However, these are often 
not received6 7 due to difficulties in access or 
service shortages.
Systematic reviews of randomised controlled 
trials evaluating mindfulness meditation have 
shown benefit in chronic pain conditions 
(positive effects on depression, quality of life 
and pain symptoms).8 9 Mindfulness is a form 
of meditation where the client attempts to 
maintain attention on the present moment, 
for example by focusing their attention on 
strengths and limitations of this study
 ► This is a randomised feasibility study designed spe-
cifically to test whether evaluation of the interven-
tion is viable in a full- scale randomised trial.
 ► The trial achieved target recruitment demonstrating 
feasibility of recruiting patients to trials of apps for 
women experiencing chronic pelvic pain.
 ► Measures of adherence to the app interventions 
were robust and complete as they relied on system- 
generated data.
 ► This trial evaluated only one app provided by a lead-
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their breathing. Whenever attention wanders from the 
present moment to thoughts and feelings, the client will 
simply take notice of them and let them go as attention is 
returned to the present. There is an emphasis on simply 
taking notice of whatever the mind happens to wander 
to and accepting each object without making judgements 
about it or elaborating on its implications additional 
meaning or need for action. The client is further encour-
aged to use the same general approach outside of their 
formal meditation practice, bringing awareness back to 
the here and now, whenever they notice a general lack 
of awareness or they notice that attention has become 
focused on streams of thoughts and worries.10 So far no 
randomised controlled trials of mindfulness meditation 
exist in chronic pelvic pain in women, but results from 
uncontrolled studies comparing pretreatment and post- 
treatment outcomes have suggested there may be a benefit 
(such as increased ability to control pain, improvements 
in mental health, emotional well- being, work and family 
life and social functioning).11 12
Mindfulness meditation can be resource intensive and 
typically requires multiple face- to- face visits over a period 
of weeks or months.13 If effective, delivery of mindful-
ness meditation via smartphone app to women with 
chronic pelvic pain could provide a new treatment option 
for this patient group, requiring a minimal increase in 
resources for healthcare systems. No studies have eval-
uated mindfulness mediation via smartphone app for 
women with chronic pelvic pain. We therefore conducted 
a randomised feasibility trial to assess the feasibility of a 
future full- scale, multicentre randomised trial of a mind-
fulness meditation intervention delivered by the Head-
space smartphone app (Headspace Ltd) for patients with 
chronic pelvic pain.
The primary objective of the study was to assess the feasi-
bility of implementing a randomised trial of a mindful-
ness meditation intervention delivered by a smartphone 
app for women with chronic pelvic pain. Specifically, we 
assessed feasibility of recruitment, levels of adherence 
to the intervention, and estimated parameters required 
for the sample size calculation for a full trial. Secondary 
objectives were to measure the clinical outcomes that 
may be used in a future full- scale trial and make esti-
mates for the effect of the intervention. We examined 
a variety of clinical outcomes assessing pain acceptance 
and self- efficacy, pain- related disability, mental health, 
mindfulness, and sexual health, and quality of life. No 
primary outcome was specified because this was a feasi-
bility study;14 however, it was anticipated that chronic 
pain acceptance would be the primary outcome for any 
future study assessing effectiveness. Pain acceptance was 
chosen by the study group with input from pain patients 
and clinicians because it has been shown to be a mean-
ingful clinical outcome that was improved by mindful-
ness mediation in other pain conditions.8 This article 
reports quantitative findings; qualitative findings will be 
published separately.15
MethODs
study design and participants
This three- arm parallel group randomised feasibility trial 
was conducted at two gynaecology clinics within Barts 
Health National Health System (NHS) trust. Eligible 
patients were aged 18 years or over had been experi-
encing chronic pelvic pain with or without identifiable 
pathology (ie, organic or non- organic chronic pelvic 
pain) for 6 months or more, and understood simple 
English. Patients were excluded from the trial if they had 
no access to a personal computer or smartphone, or were 
current users of the publicly available Headspace app. 
Patients were recruited via pelvic pain or endometriosis 
clinics at participating sites as well as at other routine 
appointments. Prior to randomisation, all participants 
were provided with a patient information sheet and 
provided written informed consent. The study protocol 
has been published16 and the final version is given in 
online supplementary appendix 1.
Interventions
Full details of the interventions are available in the 
published protocol.16 Patients were randomised to receive 
mindfulness meditation, an active control or usual care 
only. All participants received usual care, which included 
watch and wait, medication and/or surgery.
Women in the mindfulness meditation group received 
access to a 60- day progressive mindfulness meditation 
course delivered via the Headspace app. The intervention 
consisted of daily, audio- guided, mindfulness meditation 
sessions. The first 10 days of the course taught basics of 
mindfulness meditation. Following this, participants were 
able to access the module on meditation that was targeted 
at chronic pain. This module was specifically designed for 
the MEMPHIS trial. Session length was 10 min for the first 
10 days, 15 min up to day 20 and 20 min up to day 60.
The active control group received access to a series of 
muscle relaxation sessions. These sessions were identical 
every day, except that their duration increased to mirror 
the increasing duration of the meditation content being 
listened to by the intervention group.
Women in the mindfulness mediation group and active 
control group were given instructions on how to install 
the app. No further face- to- face induction was given on 
how to carry out the techniques taught in the apps. To 
maintain blinding between the mindfulness meditation 
group and active control, both groups accessed their 
intervention via the same app, and received instructions 
for the same duration, delivered by the same narrator. 
Only the content of the instructions differed.
We chose to evaluate an existing commercial app 
teaching mindfulness by guided meditation (Headspace 
Ltd) as this approach was expected to save time and 
money compared with designing a new app from scratch. 
The Headspace app was adapted for use by chronic pelvic 
pain patients by augmenting the existing app with a 
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after completing 10 days of basic training in mindfulness 
meditation.
randomisation and blinding
Women were randomly allocated 1:1:1 to the active inter-
vention app, active control app or treatment as usual 
using random- permuted blocks (block size 27, 30, 33) 
without stratification using a centralised web- based service 
with allocation concealment. The randomisation list 
was generated using the Pragmatic Clinical Trials Unit’s 
randomisation system using a random number generator. 
Following randomisation, participants, recruiting staff 
and researchers conducting follow- up interviews were 
not blinded to whether allocation was to the treatment 
as usual group or to one of the app groups (mindfulness 
meditation or active control); however, for allocation to 
an app group they were blinded to which specific app 
group this was (mindfulness meditation or active control). 
The trial statisticians remained blinded to allocation until 
the statistical analysis plan had been signed off, all data 
collection was completed, and the dataset was finalised.
Data collection
Data on patient adherence to the app were collected by 
Headspace Ltd. Data collection was performed automat-
ically by the app and recorded every time a participant 
completed more than 90% of a session with the app. No 
data were collected on sessions that were less than 90% 
complete. Headspace provided the trial team with a list 
of codes, which were linked to the randomisation system, 
and given to trial participants to access the app. At the 
end of the trial, data on completed sessions were trans-
ferred via a secure file transfer protocol from Headspace 
to the trial team. No data that could identify participants 
were included in this transfer. Clinical outcome measures 
were collected in person at baseline prior to randomis-
ation and via postal questionnaires or telephone at 2, 3 
and 6 months post randomisation. App satisfaction and 
usability questionnaires were collected via postal ques-
tionnaires or telephone. Shopping vouchers (£5), text 
reminders and phone calls were introduced to improve 
follow- up rates 3 months after recruitment began: shop-
ping vouchers were sent by post with each follow- up 
questionnaire; participants were sent text reminders and 
up to three attempts were made to contact participants 
by phone if questionnaire responses were not received 
within 10 days.
Outcomes
Feasibility outcomes were: time to recruit 90 patients to 
the study; SD of chronic pain acceptance questionnaire 
(CPAQ-8)17 (as this was likely to be the primary outcome 
for a future full- scale trial); proportion of participants 
completing a follow- up questionnaire at 6 months post 
randomisation; and proportion of participants not 
returning a follow- up questionnaire by post but who 
answered a telephone questionnaire at 6 months. SD of 
CPAQ was included as an outcome as this information 
would be required for the sample size calculation for a 
full trial. App usability was measured using the system 
usability scale18 and a purpose made, non- validated ques-
tionnaire developed from patient and public involvement 
(PPI) group discussion. Adherence to the app interven-
tions was measured in the following ways:
a. Number of days a patient has used the app within 60 
days of randomisation.
b. Number of weeks a patient has used the app on 3 or 
more days within the first 8 weeks from randomisation.
c. Whether the patient has used the app on at least 22 days 
within 60 days of randomisation (binary outcome).
d. Whether the patient has used the app on 3 or more 
days in 6 or more weeks within the first 8 weeks of ran-
domisation (binary outcome).
e. Whether the patient has used the app on 22 or more 
days within the first 60 days from randomisation and 
used the app on 3 or more days in 6 or more weeks 
within the first 8 weeks from randomisation (binary 
outcome).
Measures of app use were chosen following discussion 
within the trial management group and trial- steering 
group to give a complete picture of how participants were 
using the app. App use was defined as having completed 
at least 90% of a session. This definition of app use was 
changed after the trial started recruiting but before any 
data were analysed due to a change in the way data on app 
use were collected by Headspace. The original definition 
of app use was for patients to have completed at least 50% 
of a session.
The following clinical outcomes were measured at base-
line, 60 days, 3 months and 6 months post randomisation:
a. Pain acceptance score (measured by the CPAQ-8).17
b. Pain- related disability (chronic pain grade)—disability 
subscale).19
c. Quality- of- life subscales (measured by the RAND 
short form 36 health survey): social- functioning sub-
scale, pain- functioning subscale and general health 
subscale.20
d. The depression and anxiety subscales of the Hospital 
Anxiety and Depression Scale).21
e. Mindfulness (cognitive and mindfulness—revised 
scale).22
f. Self- efficacy (pain self- efficacy questionnaire).23
g. Sexual health among sexually active participants 
(sexual health outcomes in women questionnaire 
[SHOW- Q]).24
h. Sexual health pelvic problem interference score 
(SHOW- Q pelvic problem subscale).24
i. An individualised outcome (measure yourself medical 
outcome profile (MYMOP)).25
statistical analysis
A sample size of 90 participants was chosen as it would 
provide a precise estimate for the SD of the primary clin-
ical outcome (likely to be pain acceptance),26 27 which 
could be used to inform the sample size calculation of 
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Figure 1 Consolidated Standards of Reporting Trials diagram.
adequate to provide estimates of proportions for binary 
outcomes.27
Feasibility outcomes and baseline data were summarised 
using descriptive statistics. Clinical outcomes were anal-
ysed using a linear mixed- effects models with outcome 
measurement (at three follow- up time points) as the 
dependent variable and an unstructured correlation 
matrix for the residuals.28 The model included fixed 
effects for time, treatment arm, time- by- treatment inter-
actions and baseline measure of the outcome.29 Analysis 
was by intention- to- treat; all patients with an observed 
outcome for at least one of the three follow- up time 
points were included in the analysis,30 and were analysed 
according to their randomised group. Missing baseline 
clinical measures were handled using mean imputation.31 
See online supplementary appendix 2 for a full statistical 
analysis plan.
Patient and public involvement
The study design and intervention was discussed with 
a PPI group formed of 15 women who attended the 
recruiting clinics. A basic version of the app by Head-
space Ltd was made available to the group for testing. A 
patient, who bought their own experience and acted as a 
representative for a charity supporting those with chronic 
pelvic pain (CPP), sat on the trial management group 
that oversaw the conduct of the trial.
results
Feasibility outcomes
Ninety women were recruited to the trial in 145 days 
between May 2016 and September 2016. A Consolidated 
Standards of Reporting Trials diagram is shown in figure 1 
and baseline characteristics are shown in table 1, with 
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Table 1 Baseline demographics and medical history
Summary measure
Intervention (n=31) Active control (n=30) Usual care (n=29)
Demographics
Age (years) 34.8 (9.9) 35.7 (5.7) 35.0 (8.6)
Body mass index (kg/m2) 28.7 (7.0) 26.2 (5.5) 26.6 (6.3)
Living arrangements—n (%)
  Alone 1 (3.3) 2 (7.4) 3 (11.1)
  With others 29 (96.7) 25 (92.6) 24 (88.9)
Employment status—n (%)
  Employed 19 (63.3) 18 (66.7) 19 (67.9)
  Unemployed and looking for work 2 (6.7) 0 (0.0) 1 (3.6)
  At school or in full time education 2 (6.7) 1 (3.7) 4 (14.3)
  Unable to work due to long term sickness 4 (13.3) 5 (18.5) 1 (3.6)
  Looking after your home/family 3 (10.0) 3 (11.1) 2 (7.1)
  Retired from paid work 0 (0.0) 0 (0.0) 1 (3.6)
Age left full time education—n (%)
  Age 12 or less 1 (3.3) 1 (3.8) 1 (3.6)
  Age 13–16 9 (30.0) 4 (15.4) 3 (10.7)
  Age 17–19 6 (20.0) 5 (19.2) 3 (10.7)
  Age 20 or over 11 (36.7) 15 (57.7) 16 (57.1)
  Still in education 3 (10.0) 1 (3.8) 5 (17.9)
Ethnic group—n (%)
  White 10 (35.7) 10 (43.5) 15 (53.6)
  Black 6 (21.4) 4 (17.4) 3 (10.7)
  Central Asian 1 (3.6) 1 (4.3) 0 (0.0)
  Middle Eastern 0 (0.0) 0 (0.0) 1 (3.6)
  Southern Asian 8 (28.6) 7 (30.4) 3 (10.7)
  Mixed 0 (0.0) 0 (0.0) 2 (7.1)
  Other ethnic group 2 (7.1) 1 (4.3) 3 (10.7)
  Do not wish to say 1 (3.6) 0 (0.0) 1 (3.6)
Smoker—n (%)
  Yes 8 (27.6) 3 (12.5) 6 (21.4)
  No 21 (72.4) 21 (87.5) 22 (78.6)
  If yes, number of cigarettes per week 23.9 (20.3) 40.0 (20.0) 47.6 (35.6)
Drink alcohol—n (%)
  Yes 10 (34.5) 9 (36.0) 15 (55.6)
  No 19 (65.5) 16 (64.0) 12 (44.4)
  If yes, number of units per week 5.7 (5.3) 8.3 (4.7) 7.7 (7.2)
Baseline medical history
Duration of pain—n (%)
  0–6 months 2 (6.7) 0 (0.0) 0 (0.0)
  7–12 months 2 (6.7) 4 (14.8) 2 (7.1)
  1–2 years 3 (10.0) 5 (18.5) 5 (17.9)
  3–5 years 13 (43.3) 7 (25.9) 6 (21.4)
  6–10 years 4 (13.3) 4 (14.8) 3 (10.7)
  More than 10 years 6 (20.0) 7 (25.9) 12 (42.9)
Pain over the past week (scale of 0–10) 6.9 (2.3) 5.8 (2.8) 6.8 (2.3)
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Number of days a patient has used the app
(within 60 days of randomisation)
1.8 (4.3) 7.0 (10.5)
Number of weeks a patient has used the app on 3 or more days (within the first 8 weeks from 
randomisation)
0.3 (0.8) 1.0 (1.6)
Used the app on 22 or more days within the first 60 days from randomisation—n (%) 0 (0.0) 2 (7.1)
Used the app on 3 or more days in 6 or more weeks (within the first 8 weeks from 
randomisation)—n (%)
0 (0.0) 0 (0.0)
Used the app on 22 or more days within the first 60 days and used the app on 3 or more days 
in 6 or more weeks within the first 8 weeks from randomisation—n (%)
0 (0.0) 0 (0.0)
*Two participants in the active control group withdrew permission for their data to be used and are excluded from this analysis.
Figure 2 Daily app use (defined as completing >90% of a session) within 60 days of randomisation in the intervention and 
active control groups.
appendix 3, tables 1 and 2. Follow- up at 6 months was 
68% in the mindfulness meditation group, 53% in the 
active control group and 69% in the usual care group. 
Follow- up rates by method of follow- up (phone or ques-
tionnaire), at different time points, and a comparison of 
baseline characteristics by questionnaire completion are 
given in online supplementary appendix 3, tables 3–5 and 
figure 1. The SD for CPAQ can be found in online supple-
mentary appendix 3, table 6. Unintentional unblinding of 
treatment for either participants or researchers collecting 
data was rare (see online supplementary appendix 3, 
table 7).
App use was low in both groups, but was higher in the 
active control group than the intervention group (app 
used on mean 1.8 days intervention vs 7.0 active control—
table 2). Few women used the app on more than 22 days 
within 60 days of randomisation (0 intervention vs 2 
active control). Adherence to the app intervention was 
low or entirely absent across all other measures of app 
use (table 2). Daily app use within 60 days of randomisa-
tion is summarised in figure 2. The results from the app 
usability questionnaire are shown in online supplemen-
tary appendix 3, tables 8 and 9.
Clinical outcomes
We included 27 (87%) women from the intervention 
group, 23 (77%) from the active control group and 25 
(86%) from the usual care group in the analysis of pain 
acceptance score. The 95% CIs for CPAQ (figure 3) rule 
out any strong benefit of the intervention compared 
with either the active control group or usual care group 
at any time point (higher CPAQ corresponds to better 
outcomes). The results for other clinical outcomes are 
consistent with no effect of the intervention (full results 
of clinical outcomes are shown in online supplementary 
appendix 3, tables 10–13 and figure 2).
DIsCussIOn
This trial shows that it is feasible to recruit women to a 
trial of a mindfulness meditation app. Follow- up rates 
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Figure 3 Mean (95% CI) chronic pain acceptance score (CPAQ) and estimated treatment effect (95% CI) at each follow- up time 
point (CPAQ). Higher scores indicate better health outcomes.
meant that a relatively a high proportion of participants 
could be included in the analysis. This study provides 
estimates to inform sample size calculations for future 
research.
Most participants either did not complete any sessions 
on the apps or used them extremely infrequently. The 
analyses of clinical outcomes are consistent with no 
differences in health outcome between the three study 
arms. For pain acceptance, which was considered to be a 
likely outcome for a future effectiveness trial, our results 
suggest a meaningful effect of the mindfulness medita-
tion app, delivered as it is in this trial, is unlikely. An effec-
tive intervention requires both engagement from those 
receiving it and the ability to change the targeted clinical 
outcome.32 As engagement with the mindfulness medita-
tion app evaluated in this study was very low it is unlikely 
it would be an effective intervention in the routine clin-
ical setting for women with chronic pelvic pain, unless 
delivered as part of an intervention which significantly 
enhanced rates of engagement.
In addition to the work described in this paper we 
carried out in- depth qualitative interviews in order to 
examine the reasons for low levels of user engagement. 
Suggestions are given for improving the intervention 
such as co- development, an approach to intervention 
that involves the users in the design of the intervention. 
The findings are published in the companion paper 
describing the qualitative arm of this study.15 The length 
of the intervention in this study (60 days) may also have 
been a barrier to participation and future work may want 
to explore different treatment lengths for remote- based 
mindfulness interventions.
An important lesson from this trial for future researchers 
was that intermediate follow- up points allowed for more 
participants to be included in the analysis of clinical 
outcomes than were followed up at the final time point. 
This demonstrates that utilising intermediate follow- up 
time points may help to minimise potential bias from 
missing data in trials.
The strengths of this study include randomisation of 
participants, which eliminates bias inherent in other 
designs such as before–after studies. We also blinded 
patients, recruiters and data collectors to which app group 
patients were allocated to. We used system- generated 
app data and therefore were able to obtain complete 
adherence data for all participants. One drawback to this 
method of data collection was that sessions of the app 
were only recorded as being complete if a participant 
listened to 90% of the session. This means this study may 
have underestimated app use if participants were only 
partially completing sessions. The levels of app use were 
so low, however, that this is unlikely to have had a material 
impact on the study’s results. A second limitation is that 
recruitment was limited to two hospitals in one area of 
London, this may limit the generalisability of the results 
to settings where there is higher engagement with smart-
phone apps.
In conclusion, this study had high recruitment and 
adequate follow- up rates, demonstrating that it is 
feasible to conduct randomised trials in this patient 
population. However, due to extremely low adherence, 
further randomised trials to evaluate the benefit of the 
Headspace mindfulness meditation app for women with 
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steps to improve engagement with the app are included 
in the intervention. Further discussion of reasons for low 
engagement and what could be done to improve engage-
ment may be found in the qualitative part of this study.15
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